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IT has long been recognised that carbohydrate metabolism may be abnormal
in some cases of malignant disease. In 1885 Freund described spontaneous
hyperglycaemia in patients with cancer. Rohdenburg, Bernhard and Krehbiel
(1919) and Edwards (1919), using the oral glucose tolerance test, claimed that a
decrease in carbohydrate tolerance was a constant finding in patients with malig-
nant disease. In 1922, Friedenwold and Grove suggested that this test might be
used as a diagnostic measure in carcinoma of the gastro-intestinal tract. Subse-
quent studies did not confirmtheuniformity ofthese earlier reports. Forexample,
Marks and Bishop (1957), using methods similar to those employed in this present
study, found diminished glucose tolerance in 83 per cent of 36 patients with a
variety of malignant diseases, and Benjamin (1960), using the oral glucose
tolerance test, described similar findings in 52 per cent only of 50 patients with
endometrial carcinoma. The present investigation was undertaken to assess the
incidence and severity of the disorder of carbohydrate metabolism in malignant
-disease, and to assess the effect of treatment of the malignant process on any
abnormality of carbohydrate metabolism that might have been found before
treatment.
MATERIAL AND METHODS
Two groups of patients, as shown in Table II, were studied before and after
treatment where appropriate. The first consisted ofa control group of 19 patients
in hospital for diseases other than cancer, and considered to be free from endo-
crine disease. The second group included 11 patients with recurrent or metastatic
mammary carcinoma, each at least five years past the menopause, and under
study in a double blind clinical trial of oestriol 5 mg. twice daily and stilboestrol
dipropionate 5 mg. twice daily. After treatment with one of these drugs for
periods ranging from one to three months, the intravenous glucose tolerance test
was repeated in 8 patients. Four patients with prostatic carcinoma were studied
before treatment and again three months after treatment by testicular evisceration
and dienoestrol 15 mg. thrice daily in three instances, and by testicular eviscera-
tion only in one case.
Because of the accepted view that fasting or a low carbohydrate diet may
impair carbohydrate tolerance, patients were given 200 g. dextrose daily for three
days before the test, in addition to their ordinary diet. On the 4th morning,
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while they were fasting and at rest, three specimens of capillary blood were
obtained at 5 min. intervals, and thereafter 25 g. dextrose in 50 per cent solution
were given intravenously over a period of 3 min. Capillary blood was then
taken at 10, 20, 30, 45, 60 and 90 minute intervals after this injection and blood
glucose levels were determined by enzymatic methods as " true glucose " (Keilin
and Hartree, 1945, 1948).
As suggested by Amatuzio and others (1953), results are expressed as the
" glucose increment index " (I.I.). This was obtained by plotting the logarithm
of the glucose increment for each sample (i.e., the amount by which the observed
value exceeded the mean ofthe three control values) as ordinate, against the time
in minutes as abscissa, and fitting the best straight line possible to the points
obtained. The slope of this line, expressed mathematically, provides a con-
venient index of glucose tolerance (Duncan, 1956).
RESULTS
The intravenous glucose tolerance test was carried out on 19 patients with
carcinoma of various types and on 20 control subjects. In one of the patients
with carcinoma and in one of the control subjects, the data were unsatisfactory
for estimation of the increment index and have been discarded; results are
therefore presented from 18 patients and 19 controls respectively. In 12 of the
patients with carcinoma, the test was repeated after treatment.
TABLE I.-Glucose Increment Index in Normal Subjects and
in Patients with Diabetes or Malignant Disease
Glucose increment index
Author Normal (20) Diabetic (15)
Duncan (1956) . . . Mean 3-68 Mean 1 83
S.D. +0 40 S.D. ±0*31
Range 3 15-4 62 Range 1 33-2 34
Normal (19) Cancer (36)
Marks and Bishop (1957) . Mean 4 2 Mean 2 22
S.D. ±1-52 S.D. ±0 85
Range 2 78-7 96 Range 1 02-5 22
Normal (19) Cancer (18)
Present study . . . Mean 3 56 Mean 2 81
S.D. ±0 73 S.D. ±0 91
Range 2 52-5 13 Range 1-42-4-11
The findings in the present study are summarised in Table I along with the
results obtained by Marks and Bishop (1957), and for comparison, by Duncan
(1956) in a study ofdiabetes mellitus. The normal values for the increment index
in the present study gave a range of 2-52 to 5-13 with a mean of 3-56 (± 0.73).
The range of values in patients with carcinoma was 1-42 to 4-11 with a mean of
2 81 (+ 0 91). Using thenormal values ofthepresent series, a total of 9patients
with cancer (50 per cent) had abnormal results on initial testing, 8 of them being
in Duncan's diabetic range.
In each case ofbreast cancer (except Case 4 in whom the values were identical)
the increment index rose after treatment with oestrogens, and in the 2 patients
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in whom the increment index was abnormal before treatment, the results after
treatment increased to within the normal range (Fig. 1). In each of the patients
with prostatic carcinoma the initial test was abnormal. After treatment all
values had risen to within the normal range (Fig. 1). At the time of the second
tests a clinical assessment of the patients was made. One of the patients with
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FIG. 1. Comparison of glucose increment index in mammary and prostatic carcinoma before and
after treatment.
breast cancer was considered to be clincially unchanged (I.I. difference + 0 24),
5 to be improved (I.I. mean difference + 0.18) and 2 to have deteriorated (I.I.
mean difference + 103). In the last 2, the increment index had risen, in one
instance from the abnormal to the normal range. The rise in increment index
in the prostatic carcinoma patients was accompanied by striking clinical im-
provement in all.
In Table II, individual readings of the increment index are summarised for
the controls without cancer, and for cases of cancer before treatment and, where
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TABLE II.-Glucose Increment Index in Normal Subjects and in Malignant Disease
Normal
Glucose
increment
Case index
1 3*49
2 3 03
3 3-66
4 3-62
5 3.35
6 4-83
7 4-01
8 2-56
9 4-08
10 2 83
11 2-52
12 3-33
13 3-64
14 4-48
15 5 13
16 3 90
17 2-57
18 3-20
19 3 34
Mean 3 56
S.D. ±0 73
Range 2-52-5-13
Analy8is of Significance-
Malignant disease
,~~~~~~~~~~~~~~~~~~~ A
Case
Mammary 1
Carcinoma 2
3
4
5
6
7
8
9
10
11
Prostatic 1
Carcinoma 2
3
4
5
Thyroid
carcinoma
Ovarian
carcinoma
Glucose increment index
Before After
treatment treatment Increase
3-64 3 88 0-24
3-84 5-13 1-29
2-45 2 92 0 47
3 88 3 88 0.00
3.45 3 69 0-24
3-72 3*74 0-02
1 96 2 73 0 77
2-72 2-92 0-20
2-30 -
3-74
3-48
1 87 3-36 1-49
1-68 2-69 1.01
1-42 2 76 1-34
2-32 2 99 0-67
2 29 - -
1
1
1-75
4-11
2 81 3 39
±0O91 ±0-72
1*42-4-11 2i69-5-13
Normal V. Cancer (untreated)
Normal V. Cancer (treated)
18 Cancers (untreated) V. 12 cancers (treated)
Cancer (untreated) V. Cancer (treated) 12 cases paired
Protatic Cancer (untreated) V. Cancer (treated) 4 cases paired
2-75
0-62
1 85
2-71
6-18
possible, after treatment. Analysis ofthe results showed a statistically significant
difference between the normal group and the group of patients with cancer.
This difference was no longer significant after treatment, both in the breast cancer
group and in the 4 patients with carcimoma of the prostate.
DISCUSSION
In spite of the relatively limited number of cases studied, certain conclusions
can be drawn. In the first place, using the technique described, it is evident
that only a proportion ofpatients with malignant disease have diminished glucose
tolerance; in this series 50 per cent of 18 cases compared with 83 per cent of
36 patients with a variety of malignant diseases in Marks and Bishop's (1957)
series, and 52 per cent of 50 cases ofendometrial carcinoma in the series described
by Benjamin (1960). It should be pointed out, however, with regard to Benja-
min's work, that the oral glucose tolerance test was used and that the abnormal
curves obtained were divided into " diabetic " and " mildly impaired glucose
Clinical
assessment
No change
Worse
Improved
Worse
Improved
Improved
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tolerance" curves. In addition, Benjamin found abnormal glucose tolerance in
84 per cent of 50 cases with benign glandular hyperplasia of the uterus and in
22 per cent of 100 control subjects. In view of the different methods of study
used, comparisons of these results with those summarised in Table I should only
be accepted with reserve.
It is known that apart from diabetes mellitus and malignant disease, decreased
glucose tolerance may be found in a variety of endocrine and other disorders,
such as hepatic disease, malnutrition, infectious diseases, renal disease and obesity.
We are satisfied that factors ofthis type were unlikely to account for the abnormali-
ties found in our patients.
Secondly, this abnormality can be reversed by treatment with oestrogens,
or in one instance in our series by testicular evisceration, the return of the I.1.
to normal being accompanied in the majority of cases by evidence of some re-
gression of the malignant process. Although this improvement was a striking
feature of the cases with prostatic carcinoma, and to a less extent in breast cancer
(5 out of 8 cases had improved clinically), return of glucose tolerance to normal
cannot be correlated with the success or failure of the treatment used. As far
as we are aware there are no earlier reports of improvement in glucose tolerance
in patients with cancer in response to treatment with one exception described
by Friedenwold and Grove (1922) in a patient treated by surgical resection of a
gastric carcinoma. Obviously studies to determine the effects on the I.I. of
treatment such as chemotherapy, radiotherapy and surgery would be of consider-
able interest.
It might be argued that the improvement in glucose tolerance in these patients
was related to the administration of oestrogens and not to any associated changes
in the malignant disease. Houssay (1951) has shown that oestrogens reduce
the incidence of diabetes mellitus in subtotally pancreatectomised rats. More-
over, control by oestrogens of the diabetic state associated with acromegaly
has been reported (McCullagh, Beck and Schoffenburg, 1955). The two effects
of oestrogens found in our patients, namely regression of malignant disease and
return of glucose tolerance to normal, may not be related, since the rise in the
increment index in 2 patients who deteriorated on treatment, and in one who
failed to show any appreciable change, would suggest that the increment index
may usually be expected to rise on treatment with oestrogens, whatever the
behaviour of the disease.
The cause of the decrease in glucose tolerance in malignant disease remains a
matter for speculation. It would appear unlikely that the carbohydrate meta-
bolism of cancer tissue itself could give rise to this abnormality. Cori and Cori
(1925) have shown that tumour tissue in vivo has an increased rate of glycolysis.
Also the size of tumour in patients in whom this disturbance has been demon-
strated is often very small in relation to the total body mass. Suggestions that
it may be associated with decreased peripheral utilisation of glucose have not
been substantiated (Marks and Bishop, 1957). These authors mention another,
more attractive theory, namely that there is an alteration of host tissue meta-
bolism associated with the presence of a neoplastic process. There are reports
from animal studies of defects in enzyme activity (Greenstein, 1954) including
enzymes involved in carbohydrate metabolism (Weber and Cantero, 1955) of
the tissues of the tumour-bearing host. The precise role of oestrogens in altering
this abnormality is also obscure,
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SUMMARY
The results of intravenous glucose tolerance test performed on 18 patients
with a variety of malignant diseases and on 19 control subjects are presented.
Ofthe patients with malignant disease, 50 per cent showed diminished glucose
tolerance. Where the test was repeated in 12 patients after treatment with
oestrogens, glucose tolerance was improved, in six instances from the abnormal
to the normal range.
Possible mechanisms and the significance ofthese results are discussed briefly.
We wish to thank Dr. J. A. Strong for encouragement and guidance in the
performance of the study and helpful criticism in the preparation of the paper.
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